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Background. Among the obese, the so-called metabolically healthy obese (MHO) phenotype is thought to confer a lower CVD risk
as compared to obesity with typical associated metabolic changes.The present study aims to determine the relationship of different
subtypes of obesity with inflammatory-cardiometabolic abnormalities. Methods. We evaluated 5,519 healthy, Brazilian subjects
(43 ± 10 years, 78% males), free of known cardiovascular disease. Those with <2 metabolic risk factors (MRF) were considered
metabolically healthy, and thosewith BMI≥ 25 kg/m2 and/orwaist circumferencemeetingNCEP criteria formetabolic syndrome as
overweight/obese (OW). High sensitivity C reactive protein (hsCRP) was measured to assess underlying inflammation and hepatic
steatosis (HS) was determined via abdominal ultrasound. Results. Overall, 40% of OW individuals were metabolically healthy, and
12% normal-weight had ≥2 MRF.The prevalence of elevated CRP (≥3mg/dL) and HS in MHO versus normal weight metabolically
healthy groupwas 22%versus 12%, and 40%versus 8% respectively (𝑃 < 0.001). BothMHO individuals andmetabolically unhealthy
normal weight (MUNW) phenotypes were associated with elevated hsCRP and HS. Conclusion. Our study suggests that MHO
and MUNW phenotypes may not be benign and physicians should strive to treat individuals in these subgroups to reverse these
conditions.
1. Introduction
Obesity has been clearly linked with dyslipidemia, hyperten-
sion, and insulin resistance; however not every obese patient
has these metabolic derangements [1]. A new phenotype has
been identified within the obese population who do not have
the typical milieu of obesity-related metabolic disturbances.
These patients are termed “metabolically healthy obese”
(MHO) [2–4] and were initially thought to have little or
no increased risk of cardiovascular disease (CVD) or cancer
when compared to metabolically healthy normal weight
controls (MHNW).
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Published literature is in disagreement regarding the
relative risk of disease in the MHO population. Several epi-
demiologic studies have shown that MHO participants are at
similar or decreased risk of developing CVD compared with
MHNW participants [5–11]. Studies with longer follow-up
periods (>15 years) have demonstrated thatMHO individuals
were at an increased risk of major CVD events as compared
to MHNW individuals [12, 13]. However, there are very
few studies examining the relationship between the MHO
phenotype and subclinical markers of CVD.
In addition, another subgroup of obesity has been
defined, variously referred to as “metabolically obese but
normal weight” or “metabolically unhealthy normal weight”
(MUNW) [14]. This group, in contrast to the MHO group,
displays the typical obesity related metabolic disturbances
of hyperinsulinemia, premature insulin resistance, hyper-
triglyceridemia, and possibly elevated risk of developing
diabetes and CVD [14]. There are few studies examining
vascular inflammation or hepatic steatosis (HS) explicitly in
this population.
The aim of this study was to explore the association
amongMHO, MUNW, and markers of subclinical CVD bur-
den as assessed by high sensitivity C-reactive protein (CRP)
and hepatic steatosis (HS) in individuals without overt CVD.
We sought to identifywhetherMHOandMUNWindividuals
had similar risk profiles to MHNW individuals and were
therefore at a lower risk than metabolically unhealthy obese
(MUHO) phenotypes.
2. Methods
This cross sectional study was conducted among asymp-
tomatic individuals without a history of coronary heart
disease or CVD events presenting to the Preventive Medical
Center of the Hospital Israelita Albert Einstein, Sao Paulo,
Brazil, as part of amandatory occupational health evaluation.
The studywas approved by theHospital’s Institutional Review
Board. A total of 6461 healthy subjects were evaluated.
Information collected included demographic details, self-
reported history ofmedical conditions, and use ofmedication
including antihypertensives, antidiabetics, and lipid lower-
ing medications. Anthropometric measurements included
weight, height and waist circumference.
Fasting blood samples were obtained for plasma lipids
including high density lipoprotein cholesterol (HDL), low
density lipoprotein cholesterol (LDL), triglycerides (TG),
blood glucose, liver enzymes (AST,ALT, andGGT), and high-
sensitivity C-reactive protein (hs-CRP). Elevated hs-CRPwas
defined as ≥3mg/L and was determined by immunoneph-
elometry (Dade-Behring). Presence of HS was assessed by
abdominal ultrasound [15]. All tests were performed at the
central laboratory of the Albert Einstein Hospital. Metabolic
risk factors (MRFs) were defined according to updatedNCEP
ATP III criteria as follows: triglycerides ≥ 150mg/dL; HDL ≤
40mg/dL in males or HDL ≤ 50mg/dL in females, blood
pressure≥ 130/85mmHgor on antihypertensives, and fasting
glucose ≥ 100mg/dL or on antidiabetic medications. Those
individuals with less than two MRFs were considered to be
metabolically healthy and those with two ormoreMRFs were
labeled metabolically unhealthy [16]. Obesity was defined
as BMI > 25 kg/m2 and/or waist circumference > 40 inches
in males and >35 inches in females. Four groups were
identified: metabolically healthy normal weight (MHNW),
metabolically unhealthy normal weight (MUNW), metabol-
ically healthy obese (MHO), and metabolically unhealthy
obese (MUHO).
2.1. Statistical Analysis. All statistical analyses were per-
formed with STATA Statistical Software, Release 12.0 (Stata
Corporation Inc., College Station, TX). After removing sub-
jects with missing data, 5,519 participants were included in
the analyses. Metabolically healthy normal weight individ-
uals formed the referent group. Analysis of variance tests
(ANOVA) and chi-square tests of independence were used
for continuous and categorical variables, respectively. Logistic
regression analysis was performed, adjusting for age, gender,
physical activity, LDL, and current smoking status. A 𝑃
value < 0.05 was considered to be statistically significant.
3. Results
The majority of participants were male (78%). Surprisingly,
62% of the participants were found to be obese (BMI ≥
25 kg/m2) and 37% of the participants were identified as
being MHO. Table 1 shows the baseline characteristics of
the population selected for analysis, stratified according to
metabolic status and presence of obesity. The most common
phenotypes were MHO (37%) and MHNW (34%). MHO
individuals tended to be older than the referent group but
had a lower average age than the MUHO group (𝑃 <
0.001). Almost all variables assessed including determinants
of metabolic syndrome andmetabolic parameters (LDL, total
cholesterol and liver enzymes) differed significantly across
groups.The “higher risk” values were detected in the MUHO
group, followed by the MHO, MUNW, and MHNW groups,
respectively. The prevalence of hypertension, diabetes, and
dyslipidemia was higher in the metabolically unhealthy
groups as compared to the metabolically healthy phenotypes
(Table 1).
Table 2 shows the prevalence for elevated hsCRP and hep-
atic steatosis among the four groups. The highest prevalence
of elevated hsCRP and hepatic steatosis was observed in the
MUHO group, followed by the MHO and MUNW groups.
Although individuals with both metabolic abnormalities and
obesity were at the highest risk of CRP and steatosis, the
presence of metabolic abnormalities or obesity alone was
associated with an almost 2-fold higher risk of vascular
inflammation as well as a 3–5 fold risk of steatosis, respec-
tively. In a subgroup analysis, MUNW was not associated
with increased prevalence of hsCRP ≥3 in females. Apart
from this difference, similar graded associations between
MHO and MUHO were observed in both genders for
both vascular inflammation and hepatic steatosis (Table 2),
although with lower precision, that is, wider confidence
intervals.
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Table 1: Baseline population characteristics according to metabolic status and obesity.
Metabolically
fealthy normal
weight (𝑛 = 1864)
Metabolically
unhealthy normal
weight (𝑛 = 259)
Metabolically
healthy
overweight/obese
(𝑛 = 2025)
Metabolically
unhealthy
overweight/obese
(𝑛 = 1371)
𝑃 values (between
group differences)
Age (yrs) 41 ± 9 46 ± 10 43 ± 9 47 ± 10 <0.001
Male 𝑛 (%) 1100 (59%) 209 (80%) 1731 (85%) 1264 (92%) <0.001
Metabolic syndrome determinants
BMI (kg/m2) 22.58 ± 1.73 23.47 ± 1.25 27.97 ± 2.85 29.70 ± 3.74 <0.001
Systolic BP (mmHg) 112 ± 10 121 ± 13 119 ± 10 128 ± 13 <0.001
Diastolic BP (mmHg) 73 ± 7 77 ± 8 77 ± 7 82 ± 7 <0.001
Glucose (mg/dL) 85 ± 8 90 ± 9 89 ± 8 94 ± 14 <0.001
Triglycerides (mg/dL)∗ 89 (69–117) 183 (145–236) 107 (82–137) 189 (154–245) <0.001
HDL (mg/dL) 55 ± 14 40 ± 9 49 ± 11 39 ± 9 <0.001
Hypertension 139 (7%) 116 (45%) 397 (20%) 919 (67%) <0.001
Diabetes/↑FPG 7 (<1%) 12 (5%) 13 (<1%) 183 (13%) <0.001
Dyslipidemia 462 (25%) 256 (98%) 700 (35%) 1344 (98%) <0.001
Anthropometric data
Waist (cm) 81 ± 7 86 ± 6 96 ± 9 102 ± 10 <0.001
Waist hip ratio 0.84 ± 0.07 0.90 ± 0.06 0.92 ± 0.07 0.96 ± 0.06 <0.001
Other variables
Total cholesterol (mg/dL) 199 ± 33 208 ± 41 208 ± 37 214 ± 41 <0.001
Non-HDL (mg/dL) 143 ± 35 168 ± 42 159 ± 37 175 ± 40 <0.001
LDL (mg/dL) 124 ± 31 129 ± 35 136 ± 33 134 ± 35 <0.001
AST (IU/L) 28 ± 10 30 ± 9 32 ± 11 34 ± 12 <0.001
ALT (IU/L) 29 ± 15 36 ± 16 40 ± 22 46 ± 24 <0.001
GGT (IU/L) 29 ± 21 39 ± 26 41 ± 37 52 ± 47 <0.001
hs-CRP∗ 0.8 (0.5–1.6) 1.1 (0.6–2.2) 1.4 (0.8–2.7) 1.7 (1.0–3.0) <0.001
Presence of steatosis 𝑛 (%) 152 (8%) 70 (27%) 805 (40%) 952 (70%) <0.001
Elevated CRP 𝑛 (%) 223 (12%) 44 (17%) 452 (22%) 343 (25%) <0.001
∗Data expressed as median (interquartile range).
4. Discussion
The present study shows that MHO and MUNW groups
have a higher prevalence of elevated hs-CRP levels and
hepatic steatosis as compared to MHNW group. However,
the highest prevalence of these markers was recorded in the
MUHO group.This suggests that obesity per se in absence of
metabolic risk factors is not entirely benign and is in fact asso-
ciatedwith subclinical vascular inflammation. In addition, we
also document a higher-than-expected prevalence of obesity
in otherwise healthy Brazilian subjects, possibly due to the
selection bias of government employees.
Adipose tissue is increasingly being recognized as an
endocrine organ aswell as a highlymetabolically active tissue,
responsible for production of a large number of cytokines
including TNF-𝛼 and IL-6 [17, 18]. These adipocytokines are
in turn believed to contribute to the metabolic disturbances
associated with obesity. This understanding suggests that
obesity may result in a proinflammatory metabolic state and
may explain the higher prevalence of elevated inflammatory
markers in our MHO population. The MHO population
would therefore be expected to have greater endothelial dys-
function and subclinical atherosclerotic disease as compared
to MHNW [19–21]. A recent study examined the natural
history of the MHO phenotype and found that over half of
subjects progressed to frank metabolic syndrome over a 10
year period [22]. Our results, may reflect this phenomenon,
as the MHO population is younger than that of the MUHO
cohort, thus the MHO individual may be a harbinger of
the future MUHO patient. A recent review by our team
demonstrated that the MHO phenotype was linked with
adverse CVDoutcomes; however, systemic inflammationwas
not explicitly assessed in the majority of the studies reviewed
[23]. The few that did examine systemic inflammation failed
to demonstrate a relationship with CVD outcomes. This
does not, however, disprove the present hypothesis of a
proinflammatory state being present in theMHO phenotype,
although it does raise questions about the potential clinical
implications.
Also, MUNW phenotype is thought to represent a fun-
damental dysfunction of metabolism that is thought to be
closely related to obesity, but is not uncommon among those
4 Journal of Obesity
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with normal weight. Seppa¨la¨-Lindroos et al. also documented
higher liver fat concentration and derangement of insulin
and lipid metabolism inMUNW individuals [24], suggesting
that theMUNW should be considered a high risk phenotype.
The present study is in agreement, in that an overwhelming
number of subjects who were classified as metabolically
unhealthy suffered fromdyslipidemia, which is a classical and
well established risk factor for cardiovascular disease. Unfor-
tunately, the relatively small number of individuals classified
as MUNW in our study (𝑛 = 259), limits the statistical power
of subgroup analysis exploring the possible additive effect
of hypertension and dyslipidemia on promoting vascular
inflammation.
Our findings should be considered in the light of a
few limitations. Firstly, we employed surrogate markers for
cardiovascular disease; the true risk in this population may
thus be lower than our estimates suggest; however, the
magnitude of our results makes our findings relatively robust.
Secondly, this is a cross sectional study and therefore can only
demonstrate associations and not causation. Consequently,
longitudinal studies are needed in order to assess the relation-
ship between these phenotypes, subclinical disease markers
and hard outcomes in order to accurately determine this
population’s true risk. While a growing body of literature has
suggested that this population may be at higher risk [23], no
consensus has yet been reached.
In conclusion, our study indicates that both MHO and
MUNW phenotypes are associated with higher burden of
inflammation when compared to MHNW subjects, albeit
not as strongly as the MUHO phenotype. Certainly, future
research should be devoted to refine CVD risk in these
newly appreciated subpopulations, so that physicians can
effectively identify individuals at risk for tailored therapeutic
and preventive interventions.
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